Dr Mendeleev Research And Formulation Profile
Key Indicators
- Authorised Capital ₹ 5.00 M
as on 06-07-2024
- Paid Up Capital ₹ 2.50 M
as on 06-07-2024
- Company Age 6 Year, 11 Days
- Last Filing with ROC 31 Mar 2023
- Revenue %
(FY 2021)
- Profit -152.88%
(FY 2021)
- Ebitda -291.05%
(FY 2021)
- Net Worth -4.69%
(FY 2021)
- Total Assets -0.08%
(FY 2021)
About Dr Mendeleev Research And Formulation
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 5.00 M and a paid-up capital of Rs 2.50 M, as per Ministry of Corporate Affairs (MCA) records.
Parveen, Muneet Saggu, Baljeet Kaur, and One other member serve as directors at the Company.
- CIN/LLPIN
U24290PB2018PLC048830
- Company No.
048830
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
26 Dec 2018
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Chandigarh
Industry
Company Details
- Location
Moga, Punjab, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Dr Mendeleev Research And Formulation?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Parveen  | Director | 26-Dec-2018 | Current |
| Muneet Saggu | Director | 26-Dec-2018 | Current |
| Baljeet Kaur | Director | 26-Dec-2018 | Current |
| Avtar Saggu | Director | 26-Dec-2018 | Current |
Financial Performance of Dr Mendeleev Research And Formulation.
Dr Mendeleev Research And Formulation Limited, for the financial year ended 2021, experienced no change in revenue, with a 0% increase. The company also saw a substantial fall in profitability, with a 152.88% decrease in profit. The company's net worth dipped by a decrease of 4.69%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Dr Mendeleev Research And Formulation?
In 2021, Dr Mendeleev Research And Formulation had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Macin Remedies India LimitedActive 12 years 8 monthsParveen, Baljeet Kaur and 1 more are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Dr Mendeleev Research And Formulation?
Unlock and access historical data on people associated with Dr Mendeleev Research And Formulation, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Dr Mendeleev Research And Formulation, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Dr Mendeleev Research And Formulation's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
